Diploma PLC (LON:DPLM - Get Free Report)'s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 4,276.46 ($57.85) and traded as high as GBX 4,668.32 ($63.15). Diploma shares last traded at GBX 4,638 ($62.74), with a volume of 112,410 shares traded.
Diploma Stock Down 0.2%
The stock has a market cap of £6.19 billion, a price-to-earnings ratio of 53.31, a P/E/G ratio of 2.82 and a beta of 0.75. The company has a current ratio of 2.17, a quick ratio of 0.80 and a debt-to-equity ratio of 62.17. The firm's 50 day moving average is GBX 4,142.96 and its two-hundred day moving average is GBX 4,276.46.
Diploma (LON:DPLM - Get Free Report) last issued its quarterly earnings results on Wednesday, May 21st. The company reported GBX 80.20 ($1.08) EPS for the quarter. Diploma had a net margin of 9.25% and a return on equity of 13.18%. On average, sell-side analysts predict that Diploma PLC will post 163.7995512 EPS for the current year.
Insider Buying and Selling
In other news, insider Ian El-Mokadem bought 500 shares of the business's stock in a transaction that occurred on Monday, March 24th. The shares were acquired at an average cost of GBX 3,948 ($53.41) per share, with a total value of £19,740 ($26,704.55). Also, insider Katie Bickerstaffe bought 13 shares of Diploma stock in a transaction that occurred on Tuesday, May 20th. The stock was purchased at an average price of GBX 4,982 ($67.40) per share, for a total transaction of £647.66 ($876.16). Over the last ninety days, insiders have acquired 1,346 shares of company stock worth $5,393,173. 0.52% of the stock is owned by company insiders.
About Diploma
(
Get Free Report)
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Diploma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diploma wasn't on the list.
While Diploma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
